JHU-083

JHU-083 is a prodrug that is currently being researched for its potential therapeutic applications in the treatment of cancer and neurological disorders. It is a derivative of donor methionine, an essential amino acid, and is designed to inhibit the activity of methionine aminopeptidase 2 (MetAP2), an enzyme that plays a crucial role in the growth and proliferation of cancer cells.

Mechanism of Action

JHU-083 works by inhibiting the activity of MetAP2, an enzyme that is overexpressed in many types of cancer cells. This enzyme is responsible for removing the methionine residue from the N-terminus of newly synthesized proteins, a process that is essential for protein function and cell viability. By inhibiting MetAP2, JHU-083 disrupts protein synthesis and induces cell death in cancer cells.

Therapeutic Applications

Cancer

JHU-083 is being investigated for its potential use in the treatment of various types of cancer. Preclinical studies have shown that it can inhibit the growth of cancer cells and induce apoptosis, or programmed cell death. It has also been found to enhance the efficacy of other anticancer drugs, suggesting that it could be used in combination therapies.

Neurological Disorders

In addition to its anticancer properties, JHU-083 is also being studied for its potential applications in the treatment of neurological disorders. It has been found to have neuroprotective effects in animal models of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. It is thought to exert these effects by modulating the activity of glutamate, a neurotransmitter that plays a key role in neuronal function and survival.

Safety and Tolerability

The safety and tolerability of JHU-083 are currently being evaluated in clinical trials. So far, it has been found to be well-tolerated in animal models, with no significant adverse effects reported.

See Also

• Prodrug
• Cancer
• Neurological disorders
• Methionine aminopeptidase 2
• Apoptosis
• Neurodegenerative diseases
• Alzheimer's disease
• Parkinson's disease
• Glutamate

This article is a stub related to pharmacology. You can help WikiMD by expanding it!